-
Renal Failure Dec 2024To evaluate the efficacy, effectiveness and safety of fermented mycelium (FOSM) products for preventing contrast-associated acute kidney injury (CA-AKI).
BACKGROUND
To evaluate the efficacy, effectiveness and safety of fermented mycelium (FOSM) products for preventing contrast-associated acute kidney injury (CA-AKI).
METHODS
Randomized controlled trials were searched from four Chinese and four English electronic databases and three clinical trial registries up to July 2023. Methodological quality was assessed by using the Cochrane risk-of-bias tool 2.0. Risk difference (RD) or risk ratio (RR) and mean difference (MD) were calculated along with the 95% confidence intervals (CIs).
RESULTS
Fourteen trials testing three types of FOSM products (Bailing, Zhiling, and Jinshuibao capsules) involving 1271 participants injected contrast agents were included. For the risk of bias, all trials were rated as some concerns. Compared with routine preventive procedure (RPP) (saline hydration and alprostadil), FOSM products plus RPP showed beneficial effects in reducing the incidence of CA-AKI (14.62% and 5.35%, respectively; RD -0.06, 95% CI -0.09 to -0.03). Subgroup analysis showed that Bailing/Jinshuibao plus RPP demonstrated lower incidence of CA-AKI compared to RPP. However, there was no statistically significant difference between Zhiling with RPP and RPP in the incidence of CA-AKI. Additionally, only when FOSM products were taken before injection of the contrast, it was superior to RPP in reducing the incidence of CA-AKI. There was no statistical difference in adverse events between these two groups.
CONCLUSIONS
Low certainty evidence suggests that preventive oral use of FOSM products as an adjuvant agent was safe and might decrease the incidence of CA-AKI. However, high-quality placebo-controlled trials are needed to confirm its benefit.
Topics: Humans; Acute Kidney Injury; Adjuvants, Pharmaceutic; Cordyceps; Randomized Controlled Trials as Topic; Biological Products
PubMed: 38189088
DOI: 10.1080/0886022X.2023.2300302 -
Frontiers in Bioengineering and... 2023Leathery mycelium materials, made from the vegetative part of filamentous fungi, have garnered significant interest in recent years due to their great potential of...
Leathery mycelium materials, made from the vegetative part of filamentous fungi, have garnered significant interest in recent years due to their great potential of providing environmentally sustainable alternatives to animal- and plastic-based leathers. In this systematic patent review, we provide an in-depth overview of the fabrication methods for mycelium materials as leather substitutes recently described in patents. This overview includes strategies for fungal biomass generation and industrial developments in the sector. We discuss the use of various fungal species, plasticizers, crosslinking agents, and post-processing techniques, thereby highlighting potential gaps in scientific knowledge and identifying opportunities, challenges, and concerns in the field. Our analysis suggests that mycelium materials have significant potential for commercialization, with a growing number of companies betting on this new class of biomaterials. However, we also reveal the need for further scientific research to fully understand the properties of these materials and to unlock potential applications. Overall, this patent review delineates the current state of the art in leathery mycelium materials.
PubMed: 37609120
DOI: 10.3389/fbioe.2023.1204861